Treat cancers by targeting survivin: just a dream or future reality?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Survivin (BIRC5) discovered in 1997, initially known for apoptosis inhibition.
• Its functions now encompass mitosis, autophagy, and DNA repair, highlighting complex roles in cancer.

Purpose of the Study:

• To review the molecular functions of survivin.
• To discuss the progress and challenges in developing survivin-targeting therapies.
• To explore future directions for survivin inhibitor development.

Main Methods:

• Literature review of survivin's molecular functions.
• Analysis of survivin inhibitor development progress.
• Discussion of structural and biochemical differences between inhibitors.
• Identification of challenges in clinical application.

Main Results:

• Survivin's functions are more complex than initially understood, involving multiple cellular processes.
• Survivin inhibitor development has lagged behind other cancer therapies.
• Various survivin inhibitors exhibit distinct structural and biochemical properties.

Conclusions:

• Despite extensive knowledge of survivin's roles, clinical translation of survivin inhibitors remains a challenge.
• Further research is needed to overcome hurdles in developing effective survivin-targeted therapies.
• Future strategies may focus on novel inhibitor designs and overcoming resistance mechanisms.